Top Links

Articles Related to GFR

Pulmonary Adenocarcinoma Transforming into Small Cell Carcinoma: An Extreme Rarity

Primary small cell lung cancer (SCLC) showing epidermal growth factor receptor (EGFR) mutation is extremely rare. Transformation into SCLC has been reported as an evolution of lung adenocarcinoma acquiring resistance to EGFR tyrosine kinase inhibitors (TKI) and is considered to be a rare resistance mechanism of EGFR-TKI therapy.
View complete article: PDF  |  Full-text

Liquid Biopsy in Advanced Gastric Malignancy and Molecular Targeted Therapy; a Case Report and Update Pertaining Anti HER2-Neu Therapy

Human epidermal growth factor receptor 2 (HER2) is responsible for the pathogenesis and poor outcomes of several types of cancers, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs on the other hand, such as trastuzumab, prolong overall survival and progression-free survival in HER2-positive gastric cancer. The purpose of the case report is to evaluate the impact of delivering trastuzumab in advanced gastric cancer with concomitant HER2 mutation and amplification.
View complete article: PDF  |  Full-text

The Prevalence of Obesity among Subjects with Chronic Kidney Disease – Cross Sectional Study of Sri Lanka Population

The burden of chronic kidney disease (CKD) is growing rapidly around the world, particularly in Asia. Over the last two decades Sri Lanka has experienced an epidemic of CKD, especially in the “Mahaweli” river basin in North Central region of the island that was not attributable to conventional risk factors - hence widely termed “CKD-unknown”.
View complete article: PDF  |  Full-text

Phase II Trial of Lower Dose Bevacizumab and Irinotecan in Relapsed High Grade Gliomas

Relapsed high-grade gliomas (HGG) respond poorly to known chemotherapeutic agents with a median survival of 3 to 6 months. Several phase II trials of Bevacizumab for salvage therapy, reported excellent response rates. The optimal dose of Bevacizumab in GBM has not been defined to date. We performed a prospective phase II trial of bevacizumab using 5 mg/kg every 2 weeks.
View complete article: PDF  |  Full-text

Drug Tolerability and Outcomes in Kidney Transplant Recipients Treated with Two Formulations of Mycophenolic Acid

Mycophenolic Acid (MPA) is one of the most widely used immunosuppressive agents in kidney transplantation. This study was designed to compare the safety, tolerability and efficacy of two formulations of mycophenolic acid, Mycophenolate Mofetil (MMF) and Enteric-Coated Mycophenolate Sodium (EC-MPS), in renal transplant recipients.
View complete article: PDF  |  Full-text  | Digital
 
 


Editorial Board Members Related to GFR

Xiaodong Ma

Associate professor
College of Pharmacy
Dalian Medical University
China

AMY H. TANG

Associate Professor
Department of Microbiology and Molecular Cell Biology
Eastern Virginia Medical School
United States
Submit Manuscript